March 20, 2012 Critical Path Institute Honors World Tuberculosis Day 2012 Tuberculosis (TB) is often thought to be a disease of the past. The reality: Because no new therapies for TB have been developed i
March 6, 2012 Could Genetics Improve Warfarin Dosing? In a large-scale study and an upcoming clinical trial, scientists supported by the National Institutes of Health address one of th
February 1, 2012 Critical Path Institute Announces New CEO Critical Path Institute (C-Path) announced today that Dr. Carolyn Compton has joined the organization as its new president and chi
January 24, 2012 European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
December 23, 2011 C-Path Recognized in One of The National Institute of Mental Health’s Top 10 Research Advances of 2011
December 21, 2011 Critical Path Institute and Hamner Institutes for Health Sciences Announce Collaboration to Improve Safety of Medical Product Development Critical Path Institute(C-Path)and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a
December 2, 2011 Critical Path Institute Gathers Cross-Sector Innovators at Global Conference on Drug Development Hundreds of leaders from cross-sector arenas in government, academia, the biotechnology and pharmaceutical industry, and patient a
November 10, 2011 CPTR Yields Progress: New Five-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Sanofi, Tibotec, TB Alli
November 2, 2011 C-Path Joins Leading Voices and Organizations in Alzheimer’s Research, Drug Discovery and Care to Call for Dramatic New Strategy to Stop Alzheimer’s Disease in Report Out Today Leaders Engaged on Alzheimer’s Disease (LEAD) was created in February 2008 as an open network of Alzheimer’s-serving o
October 29, 2011 C-Path’s Avilés Discusses Importance of Data Standards in FDA Week Article FDA is encouraging industry to use newly crafted therapeutic data standards — such as utilization of qualified biomarkers